REACTION BIOLOGY CORP has a total of 12 patent applications. It decreased the IP activity by 100.0%. Its first patent ever was published in 2010. It filed its patents most often in WIPO (World Intellectual Property Organization), United States and Canada. Its main competitors in its focus markets pharmaceuticals and organic fine chemistry are NOVARTIS INT PHARMACEUTICAL LTD, MEDIVATION TECHNOLOGIES INC and MOORE II BOB M.
# | Country | Total Patents | |
---|---|---|---|
#1 | WIPO (World Intellectual Property Organization) | 5 | |
#2 | United States | 4 | |
#3 | Canada | 1 | |
#4 | China | 1 | |
#5 | EPO (European Patent Office) | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Organic fine chemistry |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Heterocyclic compounds | |
#3 | Therapeutic chemical compounds |
# | Name | Total Patents |
---|---|---|
#1 | Ma Haiching | 12 |
#2 | Wang Yuren | 5 |
#3 | Feng Yangbo | 5 |
#4 | Filip Sorin Vasile | 3 |
Publication | Filing date | Title |
---|---|---|
WO2019169257A1 | Histone deacetylase inhibitors and methods of use thereof | |
WO2019169267A1 | Quinoline and isoquinoline based hdac inhibitors and methods of use thereof | |
US2017360761A1 | Selective Inhibition of HDAC6 and HDAC8, and Methods of Use Thereof | |
US2017044185A1 | Histone deacetylase inhibitors and methods for use thereof | |
WO2013029043A1 | Selective kinase inhibitors | |
EP2396004A1 | Selective kinase inhibitors |